Physicians' Academy for Cardiovascular Education

All Videos

Recently added learning

Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD

Outcomes with P2Y12 inhibitors after PCI according to CYP2C19 genotype

5' education - Apr. 12, 2021 - Danny Claassens, MD

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: how are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD

Clinical outcomes with low dose vs. high dose DOAC in AF

5' education - Mar. 30, 2021 - Prof. Jan Steffel, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Personalized antithrombotic therapy after PCI

5' education - Mar. 17, 2021 - Niels van der Sangen, MD

Ketones as a possible therapeutic option for patients with CVD

10' education - Mar. 16, 2021 - B. Daan Westenbrink MD, PhD

GLP-1RA induces weight loss in adults with overweight or obesity

5' education - Mar. 2, 2021 - Prof. Robert Kushner, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

Rise in ANP might mediate benefits of ARNI in HFrEF

10' education - Feb. 16, 2021 - Sean Murphy, MD

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD

No decrease in thrombotic complications in second COVID-19 wave

5' education - Feb. 4, 2021 - Fleur Kaptein, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Older adults should also be treated to lower LDL-c

5' education - Jan. 18, 2021 - Prof. Børge Nordestgaard, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
5 Things a cardiologist needs to know about GLP-1RA

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

Strengths and limitations of one-month DAPT trial

3' education - Nov. 19, 2020 - Róisín Colleran, MD

Comparing P2Y12 inhibitors in patients undergoing elective PCI

3' education - Nov. 19, 2020 - Jur ten Berg, MD, PhD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

What is the value of a polypill with or without aspirin?

3' education - Nov. 16, 2020 - Prof. Salim Yusuf, MD

Side effects in a trial with statin, placebo and tablet-free periods

3' education - Nov. 16, 2020 - Prof. Darrel Francis, MD

Introduction: The evolving role of triglycerides

10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD

No effect of omega-3 fatty acids and vitamine D supplements on incident AF

3' education - Nov. 15, 2020 - Christine Albert, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Benefit with cardiac myosin activator in HFrEF

3' education - Nov. 14, 2020 - Prof. John Teerlink, MD

Detection of widespread atherosclerosis in Swedish population

3' education - Nov. 14, 2020 - Prof. Göran Bergström, MD, PhD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD

Strong evidence for colchicine in patients with chronic coronary disease

5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

Cardiovascular outcomes & atherosclerosis: How do GLP-1RA provide benefit?

10' education - Sep. 24, 2020 - Jorge Plutzky, MD - Online CME

Discussion: Novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides

10' education - Sep. 23, 2020

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI

3' education - Sep. 15, 2020 - Prof. Freek Verheugt

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Panel discussion: Expanding focus for cardiologists - The diabetic patient and cardiovascular outcomes

10' education - Sep. 9, 2020 - Prof. Ulf Landmesser - Online CME

The cardiology challenge to manage CV risk in diabetes

10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD

Advantages of the digital 2020 ESC Congress

3' education - Sep. 1, 2020 - Prof. Barbara Casadei, MD

Colchicine reduces primary outcome in chronic coronary disease

3' education - Aug. 31, 2020 - Mark Nidorf, MD

Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI

5' education - Aug. 31, 2020 - Prof. Menno Huisman, MD

A step ahead in the management of HFmrEF and HFpEF

3' education - Aug. 31, 2020 - Prof. Burkert Pieske, MD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated

3' education - Aug. 30, 2020 - Prof. Barbara Casadei, MD

Aspirin superior to DAPT for bleeding in patients treated with TAVI

3' education - Aug. 30, 2020 - Jorn Brouwer, MD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Early rhythm control in AF patients improves outcomes

3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Cardiac abnormalities in recovered COVID-19 patients

3' education - July 29, 2020 - Prof. Rudolf de Boer, MD, PhD

MI more often missed in women

5' education - July 28, 2020 - Yldau van der Ende, MD, PhD

Getting better at diagnosing HFpEF - sharing clinical practice experience

15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Improving outcomes for patients following an admission with ADHF

15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy

3' education - May 8, 2020 - Enrico Baldi, MD

Venous thromboembolism in COVID-19 patients

5' education - May 6, 2020 - Prof. Saskia Middeldorp

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

COVID-19, ACE2 and RAAS inhibition

Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

COVID-19 associated thrombotic complications

5' education - Apr. 22, 2020 - Erik Klok, MD, PhD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Use of ARNI in HFpEF patients reduces NT-proBNP levels

3' education - Apr. 8, 2020 - Jonathan Cunningham, MD

Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI

3' education - Apr. 7, 2020 - Prof. George Dangas, MD, PhD - ACC 2020

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

Higher rate of smoking cessation with e-cigarettes compared to counseling

3' education - Apr. 1, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Added value of sGC stimulator in worsening HFrEF patients

3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020

CAPACITY COVID: a registry of CV variables in patients with COVID-19

3' education - Mar. 31, 2020 - Prof. Folkert Asselbergs, MD, PhD

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events

3' education - Mar. 29, 2020 - Dr. Marc P. Bonaca, MD - ACC 2020

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence

10' education - Mar. 29, 2020 - Prof. Menno Huisman - ACC 2020

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

Challenges in prescribing DOACs for stroke prevention in AF

5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

Addressing CV risk: the role of statins and ezetimibe

5' education - Feb. 9, 2020 - Prof. Christopher Cannon, MD

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

The mechanism of action of bempedoic acid

Feb. 2, 2020

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - AHA 2019, Philadelphia

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS

3' education - Nov. 18, 2019 - Usman Baber - AHA 2019, Philadelphia

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Fish oil treatment reduces several plaque parameters after 9 months

3' education - Nov. 18, 2019 - Prof. Matthew Budoff - AHA 2019, Philadelphia

Benefit on QoL with revascularization proportional to severity of angina symptoms

3' education - Nov. 18, 2019 - Prof. John Spertus - AHA 2019, Philadelphia

Patients with moderate ischemia on a stress test do not need to go straight to the cathlab

3' education - Nov. 18, 2019 - Prof. Donald Lloyd-Jones - AHA 2019, Philadelphia

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

New generation of teenagers made addicted to nicotine: it is time to act

3' education - Nov. 16, 2019 - Mariell Jessup, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

Biochemical urine test to measure medical adherence in hypertension

5' education - Oct. 24, 2019 - Paris, France - Dan Lane

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Betablocker use associated with reduced mortality in HFrEF patients >80 years

5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD

Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients

3' education - Oct. 21, 2019 - Prof. Freek Verheugt, Amsterdam - ESC 2019, Paris

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD

NP metabolism associated with clinical outcomes in HF

5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD

Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Tamar de Vries, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

CVD in women

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Cecilia Linde - ESC 2019, Paris

What is mendelian randomization?

5' education - Oct. 10, 2019 - Paris, France - Prof. Børge Nordestgaard

A life course perspective on benefits of lower cholesterol

5' education - Oct. 9, 2019 - ESC 2019, Paris, France - George Thanassoulis

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI

3' education - Oct. 7, 2019 - Prof. Hans Erik Botker - ESC 2019, Paris

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Challenges in targeting residual risk in diabetic patients, post ACS

10' education - Sep. 25, 2019 - Prof. Peter Libby, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Substantial reduction in LDL-c with PCSK9i in the very high-risk acute setting of ACS

5' education - Sep. 24, 2019 - Paris, France - Konstantinos C. Koskinas, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand

Decreased CV risk with an intervention targeting identified barriers to care

3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm

Almost significant effects on CV outcomes with ARNI in HFpEF

3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD

Reduced NT-proBNP associated with reverse cardiac remodeling after initiation of ARNI in HFrEF

5' education - Sep. 20, 2019 - Paris, France - James Januzzi, MD

Long-term exposure to modestly lower LDL-c and SBP substantially reduces lifetime CV risk

5' education - Sep. 19, 2019 - Brian Ference, MD - Cambridge, UK

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

5' education - Sep. 12, 2019 - Prof. Alberico Catapano

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Paris, France - Prof. Salim Yusuf

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Importance of continuous use of secondary prevention therapy after CABG

3' education - Sep. 3, 2019 - Erik Björklund

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

All-cause mortality benefit with ICD use in STEMI patients treated with primary PCI

3' education - Sep. 3, 2019 - Danielle Haanschoten

Primary PCI is the best strategy for STEMI patients compared to fibrinolysis

3' education - Sep. 2, 2019 - Michael Maeng, MD

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

10-year outcomes with CABG versus PCI in patients with three-vessel disease or left main CAD

3' education - Sep. 2, 2019 - Daniel Thuijs

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Community-wide salt restriction reduces blood pressure and incidence of hypertension

3' education - Sep. 2, 2019 - Paris, France - Prof. Jaime Miranda

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD

Structural determinants of Lp(a) pathogenicity

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Marlys Koschinsky, PhD

Managing hyperkalemia in cardiorenal patients: novel therapeutic insights to optimize outcomes

10' education - Aug. 28, 2019 - Prof. Matthew Weir, MD - Online CME

Are we ready for prime-time Lp(a) assay standardization?

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina

LDL vs Lp(a) cholesterol: confounding

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD

Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients

5' education - Aug. 26, 2019 - Joost Beusekamp

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Associations of Lp(a) with CV morbidity and mortality

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Phase II data on Lp(a) lowering, followed by NHLBI recommendation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas

Lp(a) contribution to PCSK9-antibody benefit in ODYSSEY-OUTCOMES and FOURIER

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Wouter Jukema, MD, PhD

A novel parameter for proximal tubular function in HF

5' education - Aug. 21, 2019 - Lisa Emmens

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME

Higher dose of loop diuretics limits uptitration RAASi in HFrEF

5' education - Aug. 20, 2019 - Jozine ter Maaten

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Entry of Lp(a) into the CV arena

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

Lp(a) apheresis and CVD risk modulation

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD

Lp(a) and calcification in aortic stenosis

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Positive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD

More intelligent intervention through more strategic use of CV biomarkers

3' education - May 28, 2019 - Maastricht, The Netherlands

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

Growing importance of lowering remnants, also in light of the obesity epidemic

3' education - June 3, 2019 - Børge Nordestgaard

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

3' education - June 3, 2019 - John Chapman, DSc

ARNI as first-line therapy in de novo HFrEF patients after ADHF event

3' education - June 3, 2019

Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF

3' education - June 3, 2019

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD

Genetic variants and elevated risk of CAD

3' education - May 28, 2019 - Heribert Schunkert, MD - Munich, Germany

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - May 22, 2019 - ISN-WCN 2019 - Mark Cooper, MD

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Detection of AF with wearable technology to prevent stroke

3' education - Apr. 8, 2019

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients

3' education - Apr. 8, 2019 - Jorrit Lemkes

Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction

3' education - Apr. 8, 2019 - Dr. Eri Kato, Kyoto, Japan

ACDF Brief comments: The evolving role of SGLT2 inhibitors

3' education - Apr. 3, 2019 - Hanoi, Vietnam - Prof Mark Cooper, Melbourne, Australia - Asian Cardio Diabetes Forum 2019

ACDF Brief comments: The evolving role of SGLT2 inhibitors in heart failure?

3' education - Apr. 3, 2019 - Hanoi, Vietnam - Asian Cardio Diabetes Forum 2019

ACDF Brief comments: Key challenges in reinforcing CV risk management among diabetic patients

3' education - Apr. 3, 2019 - Hanoi, Vietnam - Prof John E Deanfield - Asian Cardio Diabetes Forum 2019

ACDF Brief comments: What has changed significantly in evaluating and considering CV risk in managing patients with diabetes?1

3' education - Apr. 3, 2019 - Hanoi, Vietnam - Prof. John E Deanfield - Asian Cardio Diabetes Forum 2019

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Lecture: The Kidney: Opportunities for protection and prevention

Lecture - Mar. 31, 2019 - Hanoi, Vietnam

Lecture: Heart Failure: The next frontier for SGLT2 inhibitors?

Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. Nikolaus Marx, Aachen, Germany

Lecture: Targeting risk in patients with CVD, Diabetes or CKD: new guidelines and risk management approaches

Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. John E Deanfield, MD London, United Kingdom

Lecture: SGLT2 inhibition in CVD & Diabetes: How can we explain the benefits?

Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. Nikolaus Marx, Aachen, Germany

Lecture: Cardiovascular outcomes that will change diabetes practice: What are the key findings from recent trials

Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof Mark Cooper, MD Melbourne, Australia

Lecture: Targeting HbA1c in diabetes management: What are the key lessons from glucose lowering trials?

Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. Nikolaus Marx, Aachen, Germany

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

Long-term data confirm safety and efficacy of oral antibiotics in left-sided endocarditis

3' education - Mar. 27, 2019

TAVR vs surgery in aortic stenosis: reason for a paradigm flip?

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Janet Wyman

Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events

3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD

Substantial reduction in clinical outcomes with TAVR in aortic stenosis patients at low surgical risk

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Martin B. Leon, MD

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Lifestyle improvement forms foundation of comprehensive guideline for primary prevention

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Dr. Amit Khera

New overarching recommendations in primary prevention guideline should help implementation of advise

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Donna Arnett, MD

How are the guidelines for progressive CAD guiding us in clinical practice?

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME

Lecture: Understanding the mechanism of CV benefit: How can we explain the results of GLP-1 outcome trials

Lecture - Mar. 1, 2019 - Abu Dhabi, UAE - Stephan Jacob, MD - Tubingen, Germany

Lecture: Screening for dysglycaema - when is it meaningful and how should it be performed?

Lecture - Mar. 1, 2019 - Abu Dhabi, AE - Lars Ryden, MD -Stockholm, Sweden

Lecture: Managing glucose in patients with diabetes and CVD: What did the clinical trials tell us so far?

Lecture - Mar. 1, 2019 - Abu Dhabi, UAE - Stephan Jacob, MD - Tubingen, Germany

Lecture: Cardiovascular Risk: The emerging challenge of patients with diabetes in the UAE

Lecture - Mar. 1, 2019 - Abu Dhabi, UAE - Hani Sabbour, MD - Abu Dhabi , UAE

Lecture: Diabetes in clinical cardiology: How outcomes of new trials will impact practice

Lecture - Mar. 1, 2019 - Abu Dhabi, UAE - Lars Ryden, MD Stockholm, Sweden

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof. Eduard Montanya Barcelona, Spain

Lecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof John E Deanfield, London, United Kingdom

Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?

Lecture - Nov. 16, 2018 - Dubai, UAE - Dr Adie Viljoen Stevenage, United Kingdom

Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof Richard Hobbs, Oxford, United Kingdom

Lecture: The GLP1 landscape - refining our understanding

Lecture - Nov. 17, 2018 - Dubai, UAE - Dr Adie Viljoen, Stevenage, United Kingdom

Lecture: Screening for Diabetes: When is it meaningful and how should it be performed

Lecture - Nov. 17, 2018 - Dubai, UAE - Prof. Lars Ryden, Stockholm, Sweden

Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions

Lecture - Nov. 17, 2018 - Dubai, UAE - Prof. Richard Hobbs, Oxford

Lecture: Diabetes: The new challenge in cardiovascular risk management

Lecture - Nov. 16, 2018 - Dubai, UAE - Prof Lars Ryden, Stockholm, Sweden

Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice

Lecture - Nov. 16, 2018 - Dubai UAE - Prof John E Deanfield

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK - Online CME

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain - Online CME

Aspirin for primary prevention of CV events: yes or no?

3' education - Jan. 30, 2019 - Prof. dr. Freek Verheugt - Amsterdam, The Netherlands

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME

Are very low LDL-c levels safe?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - London, UK

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark - Online CME

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

Physical activity: every step counts, for everybody

3' education - Nov. 20, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA

Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort

3' education - Nov. 15, 2018 - JoAnn Manson, MD

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Yoga-based cardiac rehabilitation program improves quality of life in post-MI patients

3' education - Nov. 15, 2018 - Dorairaj Prabhakaran, MD

Not all fish oils are created equal: different compounds have different effects

3' education - Nov. 13, 2018 - Deepak Bhatt, MD - Boston, MA, VS.

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

Comprehensive US approach to stimulate physical activity should tackle obesity and improve health

3' education - Nov. 13, 2018 - Dr. Ivor Benjamin - Milwaukee, WS, USA

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Highly purified EPA reduces important ischemic events in hypertriglyceridemia

3' education - Nov. 11, 2018 - Deepak Bhatt, MD - Boston, MA, USA.

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Shared decision-making with lifetime risk model

10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands

How early do we see the CVD benefits of LDL-C lowering?

5' education - Oct. 31, 2018 - Philip Barter, MD - Sydney, Australia

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands - Online CME

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom - Online CME

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Women are not a subgroup: the importance of sex-specific analyses

10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands

U-prevent predicts lifetime risk of CV events in healthy individuals

10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK - Online CME

Direct effects of iron on human cardiomyocytes

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Harmful effects of alcohol and smoking on arterial system in adolescents

3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

Can sex-specific thresholds for hs-troponin improve diagnosis of myocardial infarction?

3' education - Aug. 28, 2018 - Prof. Nicholas Mills, Edinburgh, UK

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

Direct Factor Xa inhibitor does not mitigate worsening of heart failure in HFrEF patients

3' education - Aug. 27, 2018 - Prof. Faiez Zannad, Vandoeuvre Les Nancy, France

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Laboratory investigation of lipids and lipoproteins

10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME

Diabetes & Obesity in HFpEF: New targets in heart failure management

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Prof. Rudolf de Boer - Groningen, The Netherlands - Online CME

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

Mendelian randomization studies can inform study design of RCTs, to set up naturally randomized trials

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

How to manage DOAC-related bleeding

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Statin-associated muscle symptoms: real or nocebo effect?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME

The ORBITA trial: is PCI beneficial in stable angina patients?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. William Boden, Boston, MA, USA

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME

Mutated bone marrow stem cells may link aging, cancer and atherosclerosis

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - Prof. Peter Libby, Boston, MA, USA

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

Appropriate use of NOACs: What is the state of the art for 2018?

15' education - Feb. 20, 2018 - Prof. John Eikelboom, McMaster University, Hamilton, Ontario, Canada

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

Practical guidance on NOACs and safety: How to deal with challenging situations in AF

15' education - Feb. 20, 2018 - Prof. John Eikelboom - Hamilton, ON, Canada

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Reversal agent for FXa inhibitors is effective and safe in interim analysis of ANNEXA-4 trial

3' education - Mar. 11, 2018 - Prof. Stuart Connolly, Hamilton, ON, Canada

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Ticagrelor non-inferior to clopidogrel for bleedings in post-STEMI patients

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - Otavio Berwanger - São Paulo, Brasil

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA

A threefold role of cardiologists as advocates for better cardiology care

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, VS - Mary Norine Walsh, MD - Indianapolis, IN, USA

Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA

Giving NOAC treatment at myocardial injury after non-cardiac surgery lowers major vascular complications

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - P.J. Devereaux - Hamilton, ON, Canada

Total mortality, but not sudden cardiac death, lower by wearable cardioverter-defibrillator in the immediate post-MI period with low EF

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL. USA - Jeffrey Olgin (San Francisco, CA, USA

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

Anticoagulation 2017: The key lessons and implications from recent clinical trials (2)

15' education - Jan. 12, 2018 - Prof. John Eikelboom - Hamilton, ON, Canada

HbA1c in CVD

10' education - Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom - Online CME
Also as CME e-learning

Inflammation & CVD: Translating insights from vascular biology to the clinic

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017

Anticoagulation 2017: The key lessons and implications from recent clinical trials (1)

15' education - Jan. 12, 2018 - Prof. John Eikelboom - Hamilton, ON, Canada

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME
Also as CME accredited e-learning

The new era of residual risk reduction

10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME

The patient with inflammatory residual risk: Who is it?

10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Staggering results for weight reduction in T2DM

3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Neurotoxin injection did not prevent the common complication of AF after cardiac surgery

3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.

New ACC/AHA hypertension guidelines empasize risk assessment

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

A coordinated effort to organise STEMI care improved treatment time and patient outcomes

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - James Jollis, MD - Chapel Hill, NC, USA

Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy

3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA - David H. Birnie, MD - Ottawa, ON, Canada

Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Sodium Bicarbonate and N-Acetylcysteine tested for the prevention of serious adverse outcomes

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Restrictive transfusion is non-inferior to liberal approach during cardiac surgery

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - David Mazer - Toronto, Ont, Canada

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Insights from the first trials in epigenetics in human: What is the way forward?

10' education - Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017 - Online CME

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction

5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Cardiovascular Disease: The ongoing journey to manage the risk

Lecture - Aug. 19, 2017 - Bangkok, Thailand - Prof John E Deanfield, UCL, London, United Kingdom - CV Risk Master Class

Promise of epigenetic modulation as a target in atherosclerotic patients

10' education - Aug. 26, 2017 - Barcelona, Spain - Erik SG Stroes, MD, Amsterdam, the Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon

A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

MRA treatment early after STEMI may give mortality benefit

3' education - Aug. 30, 2017

A new challenge for precision medicine: selecting major contributing risk factors

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

The Clinical Unmet need in the patient with Diabetes and ACS

10' education - Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME

Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

After 23 years, CANTOS trial shows that inflammatory hypothesis is right

10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain

Diverse study data confirm the rationale of intensive lipid-lowering

3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

L’inflammation est critique dans la prévention secondaire des évènements cardiovasculaires

5' education - Aug. 28, 2017 - ESC 2017, Barcelona, Spain

Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease

5' education - Aug. 28, 2017 - ESC 2017, Barcelona, Spain

The journey from vascular biology to the clinic: reducing inflammation lowers CV risk

10' education - Aug. 28, 2017

Well-conducted trial confirms principle that renal denervation can lower blood pressure

3' education - Aug. 29, 2017

First time CV reduction is achieved with CETP inhibition

3' education - Aug. 29, 2017

Large population study underscores that 'all in moderation' is still good nutrition advice

3' education - Aug. 29, 2017

Higher event risk with DAPT with potent P2Y12-antagonist than with clopidogrel-based treatment

3' education - Aug. 29, 2017

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

3' education - Aug. 28, 2017

Natural randomisation shows that mode of LDL-lowering determines CV benefit

3' education - Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

3' education - Aug. 28, 2017

Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk

3' education - Aug. 27, 2017

NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD

3' education - Aug. 27, 2017

Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients

3' education - Aug. 27, 2017

HDL: moving forward after disappointing results with HDL-mimetic in CARAT study.

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain

UK: Clinical Dialogues: Lipids & Diabetes 2017

3' education - July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Nanotherapeutic solutions to reduce atherosclerotic processes in the blood vessel

3' education - Mar. 16, 2017 - VBWG - ACC 2017 - John Cooke, MD, PhD - Houston, TX, USA

How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017

HIV as a model to study effect of chronic inflammation on CV risk

3' education - Mar. 16, 2017 - VBWG ACC 2017

Lecture - Blood pressure: How do recent trial outcomes impact our hypertension management?

Lecture - June 1, 2017 - Buenos Aires, Argentina - John E Deanfield, MD – London, United Kingdom - CV Risk Master Class

Lecture - Diabetes and heart disease: Changing trends and treatment options

Lecture - June 1, 2017 - Buenos Aires, Argentina - Robert Chilton, MD – San Antonio, TX, USA - CV Risk Master Class

Lecture - Managing lipids: Integrating novel insights with gold standard therapies

Lecture - June 1, 2017 - Buenos Aires, Argentina - Kees Hovingh, MD – Amsterdam, Netherlands - CV Risk Master Class

Lecture - Managing CV Risk in Argentina: How well are we doing and where can we improve?

Lecture - June 1, 2017 - CVRMC, Buenos Aires, Argentina - Alberto Lorenzatti, MD – Cordoba, Argentina

Lecture: Cardiovascular Disease: The ongoing journey to manage the risk

Lecture - June 1, 2017 - CVRMC, Buenos Aires, Argentina - Prof. John E Deanfield, UCL, London, United Kingdom

Lowering inflammation to address residual CV risk

3' education - Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA

Type of glycemic control is more important than tight glycemic control

3' education - May 1, 2017 - ESC HF 2017, Paris

Changing therapeutic behaviour after FOURIER

10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris

Emerging therapeutic areas in lipid management and CV disease

3' education - Mar. 16, 2017 - VBWG - ACC 2017 - Sotirios Tsimikas - La Jolla, CA, USA

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris

Initiating digoxin in AF patients associated with early hazard of sudden death

3' education - Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

Diabetes and cardiovascular disease risk in China: Lessons from 20 years study of Daqing prevention study

Lecture - May 6, 2017 - Beijing, China - Prof. Guangwei Li FUWAI Hospital, Beijing - CDMC 2017

The implications of PCSK9 outcome trials for GPs

10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

T2DM & cardiovascular risk: Determinants of Risk and Implications for Choice of Therapy

Lecture - May 6, 2017 - Beijing, China - Prof. Sanjay Rajagopalan, MD Cleveland, OH, USA - CDMC 2017

Glycemic control: Are new antidiabetic treatments changing the fundamentals of diabetes management?

Lecture - May 6, 2017 - Beijing, China - Prof. Jochen Seufert, MD Freiburg, Germany - CDMC 2017

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting

3' education - Mar. 20, 2017 - Matthias Götberg - Lund University, Sweden

Blood Pressure 2017: Translating latest insights to clinical practice- key lessons from SPRINT/HOPE-3

Lecture - May 6, 2017 - Beijing, China - Prof. Richard Hobbs,MD Oxford, United Kingdom

Factor Xa inhibitor vs. aspirin in extended phase of prevention recurrent VTE

3' education - Mar. 18, 2017 - ACC 2017, Washington, DC, USA - Dr. Philip S. Wells - Ottawa, ON, Canada

RAS inhibition, Cornerstone in CV therapy: Review on current role in management of hypertension and heart failure

Lecture - May 6, 2017 - Beijing, China - Prof. Luis Ruilope, MD Madrid, Spain - CDMC 2017

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

Multidisciplinary management of CV risk: models and lessons from Spain

Lecture - May 6, 2017 - Beijng, China - Prof. Luis Ruilope, MD Madrid, Spain - CDMC, 2017

Blood Pressure control: which targets to use?

Lecture - May 6, 2017 - Beijing, China - Prof. Richard Hobbs,MD Oxford, United Kingdom - CDMC, 2017

Achieving glycemic targets: Therapeutic rationales for earlier combination therapy

Lecture - May 6, 2017 - Beijing, China - Prof. Jochen Seufert, MD Freiburg, Germany - CDMC 2017

The Changing Landscape of Obesity, Glycemia and Cardiometabolic Risk

Lecture - May 6, 2017 - Beijing China - Prof. Sanjay Rajagopalan, MD - Cleveland, OH, USA

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

PCSK9 inhibitors: From bench to bedside

10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

Troponin is an independent predictor of CV events at non-cardiac surgery

3' education - Mar. 21, 2017 - Dr. P.J. Devereaux - Hamilton, ONT, Canada

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

PCSK9 inhibitor safe for cognitive function, even at very low cholesterol levels

3' education - Mar. 19, 2017

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

3' education - Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

Tailoring oral anticoagulation in elderly patients with AF

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

Shifting priorities of care for older cardiac patients

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Daniel E. Forman, MD (Pittsburgh, PA, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)

Advancing CV care of cancer patients: Where are we now?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Javid J. Moslehi, MD (Nashville, TN, USA)

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

Blood pressure control in CKD in older people

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Prof. George L Bakris, MD (Chicago, IL, USA)
Learn more about the clinical path of PAH!

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
Learn more about the clinical path of PAH!

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè
Learn more about the clinical path of PAH!

How common is PAH and what are its risk factors?

3' education - Jan. 9, 2017 - Bologna, Italy - Prof Nazzareno Galiè - Online CME
Learn more about the clinical path of PAH!

How is PAH diagnosed?

3' education - Jan. 8, 2017 - Bologna, Italy - Prof Nazzareno Galiè - Online CME
Learn more about the clinical path of PAH!

How can PAH patients be functionally classified

3' education - Jan. 7, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
Learn more about the clinical path of PAH!

How is the prognosis of PAH established?

3' education - Jan. 6, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
Learn more about the clinical path of PAH!

Which treatment options can be pursued and which drugs are approved for PAH?

3' education - Jan. 5, 2017 - Bologna, Italy - Prof Nazzareno Galiè - Online CME

Careful implementation of PCSK9 inhibitors in clinical practice

10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Promising results in pivotal trials of novel lipid-modifying drugs

3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)
Learn more about the clinical path of PAH!

How do we follow-up PAH patients non-responsive to therapy and how can therapy be optimized?

3' education - Jan. 10, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

No clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease

3' education - Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The Netherlands

CAC reveals evidence of coronary artery calcification in third of low-risk women

3' education - Nov. 14, 2016 - AHA, New Orleans, LA, USA - Dr. Maryam Kavousi, Rotterdam, The Netherlands

Possible approaches in precision medicine for secundary CV prevention

10' education - Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Would lower than the current ApoB targets be more useful for clinical decision-making?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Bisphosphonate as a potential new treatment for CV risk reduction

10' education - Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Emerging therapies and treatment strategies in pulmonary arterial hypertension

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul R. Forfia, MD - Philadelphia, PA, USA

Introduction: Cardiovascular Diseases in Gulf

Lecture - Dec. 17, 2016 - Qatar - Dr. Nidal Asaad, Director of the Adult Cardiology Program and Senior Consultant at Heart Hospital - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Diabetes in Qatar

Lecture - Dec. 17, 2016 - Qatar - Dr. Mahmoud A. Zirie - Qatar - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Familial Hypercholesterolemia: Understanding the Role of PCSK9

Lecture - Dec. 17, 2016 - Qatar - Dr. Khalid AlRasadi- Sultan Qaboos University Hospital, Muscat, Oman - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Clinical Perspective on PCSK9 Inhibition

Lecture - Dec. 17, 2016 - Qatar - Dr Hani Sabbour , Abu Dhabi, UAE - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Updates on International Guidelines in Lipid Management

Lecture - Dec. 17, 2016 - Qatar - Dr. Khalid AlRasadi- Sultan Qaboos University Hospital, Muscat, Oman - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Lipid management in Qatar in High CV-risk Patients: Why do we need novel therapeutics?

Lecture - Dec. 17, 2016 - Qatar - Dr. Hani Sabbour, Abu Dhabi, UAE - Master Class - PCSK9 Inhibiion in Clinical Lipid Management

Evaluating strategies for lipid related CV risk: case based review of evidence

Lecture - Dec. 16, 2016 - Qatar - Dr Hani Sabbour - Abu Dhabi, UAE - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Treat to Target in Hyperlipidemia: Concept or Reality?

Lecture - Dec. 16, 2016 - Qatar - Dr Peter Lansberg, Amsterdam - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Treatment of Dyslipidemia in Diabetic Population

Lecture - Dec. 16, 2016 - Qatar - Dr. Emad Naem, Hamad Medical Corporation, Qatar - Master Class - PCSK9 Inhibition in Clinical Lipid Management

Outstanding questions and ongoing studies on the use of NOACs

3' education - Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Oral anticoagulation in daily clinical practice in varous patient populations

10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Understanding why patients do not take their medication and stimulating adherence

10' education - Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)
##FULL_TITLE##

Lipid-lowering in the elderly - considering net benefit

3' education - Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
##FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

3' education - Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##FULL_TITLE##

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Are new Incretin-based treatments changing the fundamentals of diabetes management?

Lecture - Nov. 6, 2016 - Seoul, Korea - Prof. Sanjay Rajagopalan, MD Cleveland, OH, USA - CDMC 2016 Seoul

The role of pioglitazone in the treatment of Type 2 diabetes: Update 2016

Lecture - Nov. 6, 2016 - Seoul, Korea - Prof. Guntram Schernthaner, MD Vienna, Austria - CDMC 2016, Seoul

Managing CV risk in T2DM beyond glucose

Lecture - Nov. 6, 2016 - Seoul, Korea - Prof. Richard Hobbs, MD, Oxford, United Kingdom - CDMC 2016, Seoul

Type 2 diabetes via β-cell dysfunction in East Asian people

Lecture - Nov. 6, 2016 - CDMC, Seoul, Korea - prof. Jeong Hyun Park, MD - Busan, Korea. - CDMC 216, Seoul

The changing landscape of T2DM management: Balancing new options for glycemic control & outcomes

Lecture - Nov. 6, 2016 - CDMC, Seoul, Korea - Prof. Ele Ferrannini, MD Pisa, Italy - CDMC, Seoul, Korea

Insulin resistance and beta cell failure: Relevance for diabetes development, prognosis and treatment decisions

Lecture - Nov. 6, 2016 - Seoul, Korea - Prof Guntram Schernthaner, MD, Vienna, Austria - CDMC 2016, Seoul

Acute Coronary Syndromes & T2DM: Examine the challenges for managing CV risk

Lecture - Nov. 5, 2016 - CDMC, Seoul - Prof. Sanjay Rajagopalan, MD Cleveland, OH, USA - CDMC, Seoul

T2DM & cardiovascular risk: What are the considerations for clinical practice?

Lecture - Nov. 5, 2016 - CDMC, Seoul - Prof. Richard Hobbs, MD Oxford, United Kingdom - CDMC 2016, Seoul
##FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK

T2DM & CVD: An update on current and new strategies improving outcomes

Lecture - Oct. 22, 2016 - Yogyakarta, Java - Indonesia - Neil Poulter, MD Imperial College London United Kingdom - CV Risk Master Class - 2016, Indonesia

CV Risk guidelines for Indonesia: What and how to follow?

Lecture - Oct. 22, 2016 - Yogyakarta, Indonesia - Renan Sukmawan, MD, Jakarta-Indonesia - CV Risk Master Class 2016

Guidance in CV Risk management: How to deal with international guidelines?

Lecture - Oct. 22, 2016 - Yogyakarta, Java - Indonesia - Philip Barter, MD University of Sydney Sydney, Australia - CVRM 2016 Indonesia

Blood pressure: How do recent trial outcomes impact our hypertension management?

Lecture - Oct. 22, 2016 - Yogyakarta, Java - Indonesia - Neil Poulter, MD Imperial College London United Kingdom - CV Risk Master Class - 2016, Indonesia

Managing lipids: Integrating novel insights with gold standard therapies

Lecture - Oct. 22, 2016 - CVRM 2016 Indonesia - Philip Barter, MD University of Sydney, Sydney, Australia - CVRM 2016 Indonesia

Managing CV Risk in Indonesia: How well are we doing and where can we improve?

Lecture - Oct. 22, 2016 - Yogyakarta, Java - Indonesia - Anwar Santoso, MD University of Indonesia Jakarta, Indonesia - CV Risk Master Class, Yogyakarta, Java - Indonesia

Cardiovascular Disease: The ongoing journey to manage the risk

Lecture - Oct. 22, 2016 - Yogyakarta, Java - Indonesia - John E Deanfield MD, UCL, London, United Kingdom - CV Risk Master Class 2016 - Indonesia
##FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

Interim results of new device for treatment resistant hypertension

10' education - Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Cardiovascular Disease: The ongoing journey to manage the risk

Lecture - Oct. 15, 2016 - Moscow, Russia - John E Deanfield, MD – UCL, London, United Kingdom - CVRMC 2016 Russia

CV Risk guidelines for Russia: What and how to follow?

Lecture - Oct. 15, 2016 - Moscow, Russia - Andrey Susekov MD – Central Research Laboratory, Academy of Postgraduate Education, Moscow, Russia - CVRM 2016 Russia

New European guidance in lipid management: How to deal with international guidelines?

Lecture - Oct. 15, 2016 - Moscow, Russia - Kees Hovingh, MD – AMC, Amsterdam, The Netherlands - CVRM 2016 Russia

Managing lipids: Integrating novel insights with gold standard therapies

Lecture - Oct. 15, 2016 - Moscow, Russia - CVRM 2016, Moscow

Practical challenges in CV risk management: When to start intervening in CVD?

Lecture - Oct. 15, 2016 - Moscow, Russia - Oxana Drapkina MD, PhD, Moscow, Russia - CVRM 2016

Managing CV Risk in Russia: How well are we doing and where can we improve?

Lecture - Oct. 15, 2016 - Moscow, Russia - Svetlana Shalnova, MD – Moscow, Russia - CVRM 2016

Novel approaches to target lipids: What will impact practice in the upcoming years?

Lecture - Oct. 14, 2016 - Moscow, Russia - Kees Hovingh, MD, AMC, Amsterdam - CVRMC 2016, Russia

T2DM & CVD: An update on new strategies improving outcomes

Lecture - Oct. 14, 2016 - Moscow, Russia - John E Deanfield, MD – UCL, London, United Kingdom - CVRMC 2016, Russia

CVD & Stroke: Understanding the relation and impact on risk management

Lecture - Oct. 14, 2016 - Moscow, Russia - David Waters, MD – San Francisco, USA - CVRMC 2016, Russia

CVD & the kidney: Implications for therapy

Lecture - Oct. 14, 2016 - Moscow, Russia - Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - CVRMC 2016, Russia

Practical challenges in CV risk management: Managing patients with comorbidities

Lecture - Oct. 14, 2016 - Moscow, Russia - Alexandra Konradi, MD – Federal Almazov North-West Medical Research Centre, St Petersburg, Russia - CVRMC 2016, Russia

Blood pressure: How do recent trial outcomes impact our hypertension management?

Lecture - Oct. 14, 2016 - Moscow, Russia - John E Deanfield, MD – University College London, London, United Kingdom - CVRMC 2016, Russia

challenges in CV risk management: Managing risk or risk factors?

Lecture - Oct. 14, 2016 - Moscow, Russia - Igor Sergienko, MD – Cardiology Research Complex, Moscow, Russia - CVRMC 2016, Russia
##FULL_TITLE##

Heart failure news at the ESC

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark
##FULL_TITLE##

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)
##FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Beyond statins: The role of ezetimibe in targeting residual risk

10' education - Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom

Inflammation as potential target for therapy to target residual risk post ACS

10' education - Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
##FULL_TITLE##

Mendelian randomisation study suggests that CV prevention could be simpler and more effective

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Dr. Brian Ference (Detroit, MI, VS)
##FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)

Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG OUTCOME

Lecture - July 31, 2016 - Asian Interchange on Diabetes - David Fitchett, MD – University of Toronto, Canada

CV Protection in the EMPA-REG OUTCOME Trial: A ‘Thrifty Substrate’ Hypothesis

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Update on DPP4 inhibition in T2DM: Implications from recent and ongoing trials

Lecture - July 31, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

10' education - Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Understanding Diabetic Kidney Disease: What are the best options for clinical management?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - David Fitchett, MD – University of Toronto, Canada

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Management of hyperglycemia in type 2 diabetes: Update on novel trends and developments

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, FL, USA

Diabetes in Asia: What is different from the west?

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Chaicharn Deerochanawong, MD – Rajavithi Hospital College of Medicine, Bangkok, Thailand

Role of PCSK9 in the regulation of LDL cholesterol

Sep. 12, 2016

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016

Surviving elevated Lp(a): a patient story from diagnosis to treatment

10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

A patient with elevated Lp(a): What is current clinical practice to manage this condition?

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

The future perspectives for care for patients with high Lp(a)

10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Epigenetics: A closer look at BET inhibition

Sep. 5, 2016

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome

A new dawn for heart failure treatment? -2

Lecture - Aug. 28, 2016 - Rome, Italy - Martin R Cowie, MD – London, United Kingdom
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome

PCSK9 Therapeutics and Cholesterol Optimization: On The Edge of An Era?

Lecture - Aug. 28, 2016 - Rome, Italy - Jorge Plutzky, MD - Boston, MA, USA, Erik SG Stroes, MD – Amsterdam, The Netherlands
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome

A new dawn for heart failure treatment?

Lecture - Aug. 28, 2016 - Rome, Italy - Marc A Pfeffer, MD - Boston, MA, USA
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome

How do we figure out the “optimal dose” of a NOAC for our patients?

Lecture - Aug. 28, 2016 - Rome, Italy - Samuel Z Goldhaber, MD – Boston, MA, USA
Transatlantic Dialogues on Controversies in Contemporary Cardiology 2016, Rome

When do we remain with the devil we know (the vitamin K antagonists) … in atrial fibrillation?

Lecture - Aug. 28, 2016 - Rome, Italy - Raffaele De Caterina, MD – Chieti, Italy

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

10' education - Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

BET inhibition in cardiovascular disease: A new dawn?

10' education - Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

10' education - Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##FULL_TITLE##

A changing treatment paradigm in diabetes

3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)

SGLT2 inhibition in diabetic kidney disease

3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

Diabetes and Cardiovascular Disease: A review of new outcome data impacting practice

Lecture - July 30, 2016 - Asian Interchange on Diabetes, Bangkok - David Fitchett, MD - University of Toronto, Canada

New agents to treat hyperkalaemia

3' education - July 18, 2016 - ACC 2016 - Bertram Pitt, MD
##FULL_TITLE##

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

3' education - Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom

Inflammation, the immune system and atherosclerosis

10' education - July 7, 2015 - Amsterdam IAS

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

Novel small molecule that inhibits PAI-1 in development to slow vascular aging

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA

Two additions to the therapeutic armory to treat HFrEF

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA

Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA

How to treat residual inflammatory risk?

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA

Elucidating the role of gut microbes in CVD may provide future therapeutic strategies

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA

Steps forward in lipid-lowering therapy

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA

Managing cardiorenal syndrome in the context of heart failure

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA
##FULL_TITLE##

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

3' education - May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##FULL_TITLE##

Statin lowers CV risk, in absence of LDL-c measurement

3' education - Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
##FULL_TITLE##

New 2016 ESC Heart Failure Guidelines

3' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
##FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##FULL_TITLE##

The spectrum of Heart Failure

10' education - May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

3' education - May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands
##FULL_TITLE##

Review of cardiovascular safety of DPP4 inhibitors

3' education - May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##FULL_TITLE##

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
##FULL_TITLE##

Recommendations on novel treatments should be composed sooner after publication of evidence

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Milton Packer
##FULL_TITLE##

What surprises have emerged from genetic studies of coronary artery disease?

10' education - Apr. 25, 2016 - Boston, MA, USA - Dr. Sekar Kathiresan (Boston, MA, USA)
##FULL_TITLE##

CV benefit of daily statin therapy in the HOPE-3 trial

3' education - Apr. 18, 2016 - ACC 2016, Chicago, IL, USA - Jackie Bosch
##FULL_TITLE##

Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60

3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue
##FULL_TITLE##

GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective

3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
##FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##FULL_TITLE##

ACCELERATE: No reduction of major CV events with CETP inhibition

3' education - Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD
##FULL_TITLE##

Diabetic dyslipidaemia and residual risk in the era of LDL control

10' education - Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
##FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##FULL_TITLE##

Recent advances in lowering CV risk with antidiabetic agents

3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
##FULL_TITLE##

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

3' education - Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker
##FULL_TITLE##

NOACs for Valve Disease?

3' education - Feb. 26, 2016 - VBWG Orlando - John Camm, London, UK
##FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##FULL_TITLE##

CV outcomes with medicines to control glycemia: highlights from recently completed trials

3' education - Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##FULL_TITLE##

Integrating Big Data with evidence generation for precision medicine: implications for cardiovascular disease

3' education - Nov. 7, 2015 - VBWG, Orlando FL, USA - Elliott M. Antman

The mechanism of SGLT2 inhibition in glucose control

Nov. 24, 2015
##FULL_TITLE##

HF Summit : innovation in clinical care in heart failure

10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##FULL_TITLE##

A multidisciplinary approach in heart failure management

10' education - Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
##FULL_TITLE##

Living with heart failure: A patient perspective

3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Nick Hartshorne-Evans
##FULL_TITLE##

Diagnosing Heart Failure: How, where and who?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Prof. Burkert Pieske
##FULL_TITLE##

Where are we with HF patients with AF?

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Dipak Kotecha
##FULL_TITLE##

Novel insights and innovations in targeting the neurohumoral system

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer
##FULL_TITLE##

A global overview of key developments in Heart Failure: Where are we now?

3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Dr. Kenneth Dickstein
##FULL_TITLE##

How to classify your HF patients? Understanding HFpEF versus HFrEF

3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Carolyn Lam
##FULL_TITLE##

The advent of novel nonsteroidal mineralocorticoid receptor antagonists in heart failure

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof Bertram Pitt
##FULL_TITLE##

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
##FULL_TITLE##

Major new phase in heart failure management

3' education - Nov. 9, 2015 - AHA 2015, Orlando, FL, USA - Milton Packer
##FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

10' education - Sep. 29, 2015
##FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

10' education - Sep. 29, 2015
##FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

10' education - Sep. 27, 2015
##FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015
##FULL_TITLE##

Inflammation in Acute Myocardial Infarction & Ventricular Remodelling

10' education - Oct. 21, 2015 - ESC 2015, London UK at Monday, August 31, 2015
##FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

PATHWAY-2: which agent can best treat therapy resistant hypertension?

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##FULL_TITLE##

Pharmacodynamics of investigational pre-beta HDL-mimicking agent

3' education - May 24, 2015 - ISA2015, Amsterdam - Eralp Bellibas
##FULL_TITLE##

Reassuring safety data with investigational lipid-modifying agent

3' education - May 24, 2015 - ISA2015, Amsterdam - David Kallend
##FULL_TITLE##

The mechanism of SGLT2 inhibition in glucose control

3' education - July 24, 2015
##FULL_TITLE##

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##FULL_TITLE##

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##FULL_TITLE##

Studying the cardioprotective properties of the phosphatidylserine-component of HDL

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
##FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby
##FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##FULL_TITLE##

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##FULL_TITLE##

CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
##FULL_TITLE##

Persistent lipid changes with long-term treatment with mipomersen

3' education - May 24, 2015 - ISA2015, Amsterdam - dr. Paul Barton Duell
##FULL_TITLE##

Combined hyperlipidaemia

3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Rob Hegele
##FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##FULL_TITLE##

Lipid Management: diagnostics and guidelines

3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##FULL_TITLE##

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##FULL_TITLE##

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
##FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##FULL_TITLE##

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

3' education - June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##FULL_TITLE##

Ezetimibe does not disturb glycaemic control

3' education - June 16, 2015 - ISA2015, Amsterdam - Peter Toth
##FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##FULL_TITLE##

How to manage statin-intolerant patients?

3' education - June 11, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Erik Stroes
##FULL_TITLE##

Lipids: Who is at real high risk?

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
##FULL_TITLE##

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam
##FULL_TITLE##

Lowering triglycerides while raising LDL-c: is this a problem?

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Børge Nordestgaard
##FULL_TITLE##

Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton
##FULL_TITLE##

Collective amnesia on dietary fats and LDL-c

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Prof. Martijn Katan
##FULL_TITLE##

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##FULL_TITLE##

John Chapman awarded for research on cholesterol particles

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Prof. John Chapman, Paris, France
##FULL_TITLE##

Harry Davis awarded with first Endo Award for discovery of ezetimibe

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Harry Davis
##FULL_TITLE##

Unique Dutch collaborative effort to identify FH patients

3' education - Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
##FULL_TITLE##

OSLER studies Compelling data on PCSK9 inhibition

3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
##FULL_TITLE##

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
##FULL_TITLE##

PEGASUS: Clinical judgement needed

3' education - Mar. 16, 2015 - ACC 2015, San Diego - Valentin Fuster, MD Mount Sinai Hospital, New York,NY
##FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##FULL_TITLE##

Cardiovascular effects of glucose lowering: Safety vs Efficacy

3' education - Dec. 12, 2014 - AHA, Chicago VBWG - Dr Silvio E Inzucchi
##FULL_TITLE##

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##FULL_TITLE##

IMPROVE-IT: Congratulations, results & need for expert perspectives

3' education - Dec. 4, 2014 - AHA, Chicago - Dr Patrick O' Gara
##FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##FULL_TITLE##

IMPROVE-IT: Implications for clinical practice & guidelines

3' education - Nov. 19, 2014 - Chicago, Il, USA - Prof. Kausik Ray
##FULL_TITLE##

Confirmation LDL-c lowering beyond current borders with non statin therapy is effective

3' education - Nov. 19, 2014 - Chicago, Il, USA - Prof Erik Stroes
##FULL_TITLE##

Potential role of PCSK9 inhibitors

3' education - Nov. 26, 2014 - VBWG Chicago - Michael J Koren
##FULL_TITLE##

IMPROVE-IT & LDL-c: Even lower is even better

3' education - Nov. 19, 2014 - AHA, Chicago - Dr. Lori Mosca
##FULL_TITLE##

FH in Europe: Need for a registry

3' education - Nov. 10, 2014 - Zeist, The Netherlands - dr Kees Hovingh & Eric Bruckert
##FULL_TITLE##

Critique on the new AHA / ACC guidelines for lipid management

10' education - Nov. 7, 2014 - Barcelona, ESC - Prof Kausik Ray, Imperial College London, United KIngdom
##FULL_TITLE##

First European experience with human MTP-inhibitor in HoFH

10' education - Oct. 24, 2014
##FULL_TITLE##

CV Risk Master Class Panama

10' education - Nov. 2, 2014
##FULL_TITLE##

PCSK9 inhibition: Clinical Update 2014

3' education - Oct. 29, 2014 - Snapshot 2014 - Dr Evan Stein
##FULL_TITLE##

HoFH: New insights in prevalence and therapy

3' education - Oct. 26, 2014 - Snapshot 2014 - dr Kees Hovingh
##FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##FULL_TITLE##

Is inflammation reduction key for targeting residual risk, beyond lowering LDL-c?

3' education - Oct. 18, 2014 - Snapshot 2014 - Prof. Paul M Ridker, MD
##FULL_TITLE##

CVRM Moscow 2014

10' education - Sep. 27, 2014
##FULL_TITLE##

CETP inhibition: Confusion, conflicting results but promising developments

3' education - Oct. 3, 2014 - Snapshot 2014 - Prof Philip Barter
##FULL_TITLE##

Hypertriglyceridemia: New small-molecule based strategies

10' education - Oct. 1, 2014 - Barcelona - Christie Ballantyne MD
##FULL_TITLE##

CVRM Shanghai 2014

10' education - Sep. 27, 2014
##FULL_TITLE##

Will new strategies targeting high triglycerides be beneficial?

3' education - Sep. 23, 2014 - SNAPSHOT 2014 - Prof Christie Ballantyne
##FULL_TITLE##

HDL mimetics: New promise in ACS?

3' education - Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD

CVRM Dubai

10' education - Sep. 15, 2014
##FULL_TITLE##

IMPROVE-IT: Scenarios for understanding the results

3' education - Sep. 9, 2014 - Barcelona - Prof Chris Packard
##FULL_TITLE##

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams
##FULL_TITLE##

HoFH: New insights and expanding therapeutic options

10' education - Sep. 6, 2014 - Snapshot 2014 - Dr. Kees Hovingh, AMC, Amsterdam, The Netherlands
##FULL_TITLE##

Innovating hypertension management beyond current therapies: What are the opportunities?

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##FULL_TITLE##

Diabetes and reducing CVD: Are novel interventions living up to their promise?

10' education - Sep. 5, 2014 - Snapshot 2014 - Naveed Sattar MD, Glasgow
##FULL_TITLE##

CETP inhibition: Close to a better understanding of the promise?

10' education - Sep. 4, 2014 - Snapshot 2014 - Prof. Philip Barter, Sydney, Australia
##FULL_TITLE##

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

10' education - Sep. 3, 2014
##FULL_TITLE##

Biology and validation of PCSK9 as a novel target to lower LDL-C

10' education - Aug. 30, 2014 - Barcelona, ESC - Prof. John JP Kastelein
##FULL_TITLE##

PCSK9: The promise of a new target in lipid management

10' education - Sep. 3, 2014 - Barcelona, ESC - Prof. John E Deanfield, UCL, London
##FULL_TITLE##

New registries on ACS/PCI: how does the real world look like

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##FULL_TITLE##

Latest guidelines on ACS/PCI: what are the key changes?

10' education - Sep. 2, 2014 - Barcelona, ESC - Prof. Petr Widimsky, Prague, Czech Republic
##FULL_TITLE##

ACS/PCI :Patient cases based on real world data

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##FULL_TITLE##

ACS/PCI: Patient cases based on latest guidelines

10' education - Sep. 1, 2014 - Barcelona, ESC - Professor Petr Widimský
##FULL_TITLE##

20 years clinical use of GP IIb/IIIa receptor antagonists

10' education - Sep. 14, 2014
##FULL_TITLE##

LDL cholesterol, LDL receptor & PCSK9

3' education - July 31, 2013
##FULL_TITLE##

CV Risk Master Class Jakarta

10' education - Aug. 9, 2014
##FULL_TITLE##

CVRM 2014 Ho Chi Minh

10' education - Aug. 7, 2014

Cardiovascular disease in the Gulf States: What are the issues and opportunities?

10' education - June 20, 2014
##FULL_TITLE##

Emerging therapies to lower LDL-cholesterol

10' education - May 8, 2014
##FULL_TITLE##

Translating new clinical trial data of DOACs for stroke prevention into clinical practice

3' education - Mar. 30, 2014 - VBWG at ACC - Michael Ezekowitz MD, PhD
##FULL_TITLE##

Are new hypertension guidelines helpful for patients at high risk?

3' education - May 23, 2014 - CDMC Almaty - Dr Peter Meredith, Glasgow
##FULL_TITLE##

Neurological complications in diabetes

3' education - Apr. 23, 2014 - CDMC Almaty - Boris Mankovsky
##FULL_TITLE##

Improving BP measurement for better hypertension management

3' education - Apr. 25, 2014 - CDMC Almaty - Prof Luis Ruilope, Madrid, Spain
##FULL_TITLE##

Impact of new diabetes drugs on cardiovascular outcomes

3' education - Apr. 18, 2014 - VBWG - ACC 2014 - Deepak L. Bhatt
##FULL_TITLE##

New British guidelines and risk calculator on CV Risk (JBS3)

3' education - Apr. 7, 2014 - ACC 2014 - Prof John E Deanfield

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden
##FULL_TITLE##

Cholesterol guideline breaking news in USA

3' education - Dec. 12, 2013 - AHA 2013, Dallas - Clyde Yancy
##FULL_TITLE##

ENGAGE: Factor Xa inhibitor edoxaban with promising results

3' education - Nov. 26, 2013 - AHA 2013 - Bob Giugliano
##FULL_TITLE##

LDL Receptor Function and Life Cycle

3' education - Dec. 27, 2013

CV Risk Master Class Latin American chapter

10' education - Nov. 25, 2013
##FULL_TITLE##

The challenge for CV Risk management in Latin America

10' education - Nov. 13, 2013
##FULL_TITLE##

Cannabis used as a 'clean drug'

3' education - Oct. 31, 2013 - AMC Amsterdam - Willem Mulder, Fleur van der Valk
##FULL_TITLE##

Learnings on early antiplatelet therapy from registries

10' education - Oct. 25, 2013

CV Risk Master Class

10' education - Oct. 14, 2013
##FULL_TITLE##

Inflammation: targets for intervention

3' education - Oct. 3, 2013 - Snapshot 2013 - Ulf Landmesser
##FULL_TITLE##

Options left for HDL therapies

3' education - Oct. 3, 2013 - Snapshot 2013 - Bryan Brewer
##FULL_TITLE##

Targeting fasting and post-prandial triglycerides

3' education - Sep. 1, 2013 - Snapshot 2013 - Dr. Joanne M. Donovan
##FULL_TITLE##

HoFH: Prevalence and new treatments

3' education - Sep. 1, 2013 - Snapshot 2013 - Dr Kees Hovingh

Inflammation & cardiovascular disease: Exploring new options for intervention

10' education - Sep. 30, 2013

PCSK9: the new lipid target in preventive cardiology?

10' education - Sep. 26, 2013
##FULL_TITLE##

The roadmap of PCSK9 inhibitors towards the clinic

10' education - Sep. 30, 2013
##FULL_TITLE##

PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c

10' education - Sep. 30, 2013
##FULL_TITLE##

Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?

10' education - Sep. 30, 2013
##FULL_TITLE##

CETP inhibition: Where are we now?

10' education - Sep. 14, 2013
##FULL_TITLE##

Cardiovascular risk management: What are the strategic changes?

10' education - Sep. 14, 2013
##FULL_TITLE##

Lowering of LDL-C: Novel concepts and novel promises

10' education - Sep. 14, 2013
##FULL_TITLE##

Targeting triglycerides: New insights from antisense therapy

10' education - Sep. 14, 2013
##FULL_TITLE##

HDL mimetics and plaque regression

10' education - Sep. 15, 2013
##FULL_TITLE##

Targeting HDL-C: What are the options left?

10' education - Sep. 14, 2013
##FULL_TITLE##

Atrial fibrillation & stroke prevention; What’s new?

10' education - Sep. 14, 2013
##FULL_TITLE##

Update on therapy-resistant hypertension: Novel pharmacotherapy or renal denervation?

10' education - Sep. 14, 2013
##FULL_TITLE##

Therapeutic innovations for severe hypertriglyceridemia

3' education - Sep. 10, 2013 - Amsterdam, August 31, 2013 - Prof Daniel Gaudet
##FULL_TITLE##

Therapy resistant hypertension: novel pharmacotherapy or renal denervation?

3' education - Sep. 10, 2013 - Amsterdam, August 31, 2013 - Luis Ruilope
##FULL_TITLE##

PCSK9 & LDL- The best story of translational medicine?

3' education - Sep. 8, 2013 - Amsterdam, August 31, 2013 - Dr Evan Stein

Online CV Risk Master Class

10' education - Oct. 21, 2013

Online CV Risk Master Class - Español

10' education - Oct. 31, 2013
##FULL_TITLE##

Blood Pressure: Does it matter how to lower it?

3' education - June 20, 2013 - CVRMC Kuala Lumpur - Prof. Peter Sever
##FULL_TITLE##

Diabetes, glycemic control & vascular prevention

3' education - June 16, 2013 - CDMC Hanoi - Prof John Betteridge
##FULL_TITLE##

The unmet need for controlling hypertension

3' education - June 17, 2013 - VBWG San Francisco - Dr. Domenic Sica
##FULL_TITLE##

Treating the untreatable high LDL-c

3' education - June 17, 2013 - Kuala Lumpur - Dato' dr Khoo Kah Lin
##FULL_TITLE##

HPS2-THRIVE and the future of clinical endpoint trials

3' education - May 12, 2013 - CDMC hanoi - Prof D John Betteridge

CV Risk Master Class - Middle East

10' education - May 30, 2013
##FULL_TITLE##

Preview on new hypertension guidelines

3' education - May 8, 2013 - CDMC Hanoi - Prof Michael A Weber

CardioVascular Risk Master Class

10' education - May 17, 2013

CardioVascular Risk Master Class

10' education - May 17, 2013

CV Risk Master Class - Asian chapter

10' education - May 29, 2013

CV Risk Master Class, Saturday

10' education - May 3, 2013
##FULL_TITLE##

A new prediction rule for CV diseases

3' education - May 6, 2013 - UMC Utrecht - Frank Visseren

Managing diabetes & CV risk: Focus on the evidence with PPAR agonists

10' education - May 5, 2013
##FULL_TITLE##

Emerging therapies in acute heart failure

3' education - Apr. 27, 2013 - VBWG at ACC - Dr. John R. Teerlink

BP control: Are we getting there yet?

10' education - Apr. 29, 2013
##FULL_TITLE##

Antibodies against PCSK9: A new LDL-c lowering therapy?

3' education - Mar. 31, 2013 - CVC 2013 - Dr. Kees Hovingh, Amsterdam
##FULL_TITLE##

New drugs and devices in development for hypertension

3' education - Apr. 18, 2013 - VBWG at ACC 2013 - Domenic Sica

CardioDiabetes Master Class, Asian chapter

10' education - May 30, 2013

Speakers Training Weber

10' education - May 12, 2013

Speakers Training Hobbs

10' education - Apr. 19, 2013
##FULL_TITLE##

Heart failure patients with preserved ejection fraction

3' education - Apr. 18, 2013 - VBWG at ACC 2013 - Scott Solomon

CV disease & diabetes in Asia

10' education - Apr. 15, 2013
##FULL_TITLE##

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon
##FULL_TITLE##

Update: Heart Failure and Mineralocorticoid Receptor

3' education - Jan. 5, 2013

Second electronic study

10' education - Apr. 8, 2013
##FULL_TITLE##

Dual PPAR agonists in CV risk & diabetes

3' education - Dec. 11, 2012
##FULL_TITLE##

Renal denervation: New frontier in treating resistant hypertension

3' education - Dec. 11, 2012 - LA AHA 2012 - Dr Horst Sievert
##FULL_TITLE##

Protecting the heart and the kidney

3' education - Nov. 29, 2012
##FULL_TITLE##

Reprogramming of fibro-blasts to cardiomyocytes

3' education - Nov. 25, 2012 - AHA 2012 - Prof Victor Dzau
##FULL_TITLE##

HDL Infusion may lower risk of heart attack

3' education - Nov. 16, 2012 - AHA 2012 - dr Andreas Gille
##FULL_TITLE##

LDL lowering through liver and intestine: New insights

3' education - Nov. 13, 2012
##FULL_TITLE##

Improve CV risk management in clinical practice

3' education - Nov. 2, 2012

Protein energy wasting in CKD patients

3' education - May 10, 2012

Mechanisms of CKD-MBD: New insights in the pathogenesis

3' education - May 9, 2012
##FULL_TITLE##

CKD & MBD: what are the drivers of disease?

3' education - Apr. 10, 2012
##FULL_TITLE##

CKD and CVD disease: a clinical update from KDIGO

3' education - Apr. 9, 2012
##FULL_TITLE##

CKD & Nutrition: Role of protein intake & phosphate levels

3' education - Apr. 5, 2012
##FULL_TITLE##

New evidence in the treatment of hyperphosphatemia

3' education - Apr. 4, 2012
##FULL_TITLE##

Achieving optimal glycemic control: What are the current options in management?

3' education - Dec. 7, 2011
##FULL_TITLE##

Managing blood pressure: The need for individualized treatment considerations to reach targets

3' education - Dec. 6, 2011
##FULL_TITLE##

Pioglitazone: where do we stand in 2011?

3' education - Dec. 1, 2011
##FULL_TITLE##

HDL as the next target in lipid management

3' education - Nov. 10, 2011
##FULL_TITLE##

HDL as a risk marker and as a treatment target?

3' education - Nov. 1, 2011
##FULL_TITLE##

Managing blood pressure: choosing the right strategy to meet BP targets

3' education - Oct. 28, 2011
##FULL_TITLE##

RAS Blockade in the Real World: From Clinical Trial Data to Challenges in Daily Hypertension Management

3' education - Oct. 28, 2011
##FULL_TITLE##

Expanding the role of lipid management: Current and Future

3' education - Oct. 25, 2011
##FULL_TITLE##

Towards optimal management of CV risk: What are the opportunities?

3' education - Oct. 25, 2011
##FULL_TITLE##

Acute myocardial infarction: What is new?

3' education - Oct. 3, 2011
##FULL_TITLE##

How to develop a national strategy to prevent CV disease?

3' education - Sep. 8, 2011
##FULL_TITLE##

HDL & Residual Risk

3' education - Aug. 31, 2011
##FULL_TITLE##

Diabetes & CV Risk: routine practice versus guidelines

3' education - July 29, 2011
##FULL_TITLE##

Priorities in the management of type 2 diabetes

3' education - July 29, 2011
##FULL_TITLE##

Vascular function as an early sign of trouble

3' education - July 28, 2011
##FULL_TITLE##

Confirmation of lipid hypothesis in SEAS: Mortality risk stratification without lipids

3' education - July 28, 2011
##FULL_TITLE##

Management of diabetes

3' education - July 26, 2011
##FULL_TITLE##

Inhibition of cholesterol absorption

3' education - July 25, 2011
##FULL_TITLE##

HbA1c: targets & recommendations

3' education - July 25, 2011
##FULL_TITLE##

Perspectives on Aim High

3' education - July 22, 2011
##FULL_TITLE##

Optimal blood pressure management

3' education - July 22, 2011
##FULL_TITLE##

RAS Blockade in hypertension

3' education - July 22, 2011
##FULL_TITLE##

Targeting Lifetime CV risk

3' education - July 22, 2011
##FULL_TITLE##

LDL: Future management

3' education - July 21, 2011
##FULL_TITLE##

Implications from SHARP

3' education - July 21, 2011
##FULL_TITLE##

HDL-c in CV disease

3' education - July 1, 2011
##FULL_TITLE##

Endothelium and cardiovascular disease

3' education - June 24, 2011
##FULL_TITLE##

Diabetes & vascular risk:

3' education - June 16, 2011

CV Disease in Asia

3' education - Apr. 29, 2011
##FULL_TITLE##

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##FULL_TITLE##

TZD's and CV risk-benefit

3' education - Apr. 7, 2011
##FULL_TITLE##

TZD's and CV risk-benefit

3' education - Apr. 7, 2011

schernthaner

3' education - Apr. 7, 2011
##FULL_TITLE##

Insulin and B-cell

3' education - Mar. 30, 2011
##FULL_TITLE##

Managing CHD

3' education - Mar. 29, 2011
##FULL_TITLE##

Lipids and CV risk

3' education - Oct. 3, 2009
##FULL_TITLE##

Diabetes & CV disease

3' education - Oct. 3, 2009
##FULL_TITLE##

CVD in Asia

3' education - Oct. 3, 2009
##FULL_TITLE##

The high risk cv patients

3' education - Oct. 3, 2009
##FULL_TITLE##

The vulnerable plaque:

3' education - Sep. 28, 2009
##FULL_TITLE##

Lipid management in Asia

3' education - Sep. 28, 2009
##FULL_TITLE##

CV risk in diabetes

3' education - Sep. 28, 2009
##FULL_TITLE##

Intervening in CV Risk

3' education - July 29, 2009
##FULL_TITLE##

Glycemic control

3' education - July 29, 2009
##FULL_TITLE##

Hypertension and diabetes

3' education - July 29, 2009
##FULL_TITLE##

Diabetic nephropathy

3' education - July 29, 2009
##FULL_TITLE##

Opportunities for ARB’s

3' education - July 29, 2009
##FULL_TITLE##

Compliance in diabetes

3' education - July 29, 2009

On demand 10" video

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Ketones as a possible therapeutic option for patients with CVD

10' education - Mar. 16, 2021 - B. Daan Westenbrink MD, PhD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

Rise in ANP might mediate benefits of ARNI in HFrEF

10' education - Feb. 16, 2021 - Sean Murphy, MD

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
5 Things a cardiologist needs to know about GLP-1RA

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD

Introduction: The evolving role of triglycerides

10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD

Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation

10' education - Nov. 9, 2020 - Prof. John Kastelein, MD

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD

Time to reduce implementation gaps of lipid-lowering therapy

10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD

Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy

10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD

Is there a role for PCSK9 inhibition in patients with high Lp(a)?

10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD

Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD

Why worry about high Lp(a) and how to assess Lp(a) levels?

10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

Cardiovascular outcomes & atherosclerosis: How do GLP-1RA provide benefit?

10' education - Sep. 24, 2020 - Jorge Plutzky, MD - Online CME

Discussion: Novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides

10' education - Sep. 23, 2020

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Panel discussion: Expanding focus for cardiologists - The diabetic patient and cardiovascular outcomes

10' education - Sep. 9, 2020 - Prof. Ulf Landmesser - Online CME

The cardiology challenge to manage CV risk in diabetes

10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

How will outcomes of ARNI trials impact diagnosis and management of HF?

10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD

3rd Groningen Heart failure symposium: How to implement the newest HF therapies?

10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)

10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence

10' education - Mar. 29, 2020 - Prof. Menno Huisman - ACC 2020

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Challenges in targeting residual risk in diabetic patients, post ACS

10' education - Sep. 25, 2019 - Prof. Peter Libby, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD

Managing hyperkalemia in cardiorenal patients: novel therapeutic insights to optimize outcomes

10' education - Aug. 28, 2019 - Prof. Matthew Weir, MD - Online CME

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?

10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Cardiac amyloidosis: an emerging target in HFpEF?

10' education - July 19, 2019 - Prof. van der Meer, MD, PhD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD

Assessing individual CV risk and treatment effect with U-Prevent

10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

The future of SGLT2i in HF: Managing patients without T2DM?

10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD

Real world practices and outcomes in the management of HF in T2DM patients

10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD

The essentials about diabetes and heart failure

10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK

Why could patients with HF and T2DM benefit from SGLT2i?

10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - May 22, 2019 - ISN-WCN 2019 - Mark Cooper, MD

The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK - Online CME

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - London, UK

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark - Online CME

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Shared decision-making with lifetime risk model

10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME

HFpEF: What is it & size of the problem

10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands - Online CME

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom - Online CME

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Women are not a subgroup: the importance of sex-specific analyses

10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands

U-prevent predicts lifetime risk of CV events in healthy individuals

10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Population screening for atrial fibrillation with a smartphone

10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium

Challenges and models in CV risk management: Start early, Invest in your arteries

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK - Online CME

Direct effects of iron on human cardiomyocytes

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Laboratory investigation of lipids and lipoproteins

10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa